Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute encephalopathy attributed to 5-FU

C J Langer1, A Hageboutros, D D Kloth

  • 1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Pharmacotherapy
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

British journal of cancer·2015
Same author

Ribulose-1,5-bisphosphate carboxylase/oxygenase expression in melon plants infected with Colletotrichum lagenarium : Activity, content and rate of synthesis.

Planta·2013
Same author

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

Lung cancer (Amsterdam, Netherlands)·2012

Acute encephalopathy, a rare reaction to 5-fluorouracil (5-FU) chemotherapy, is typically reversible. Treatment with steroids and thiamine may help speed up neurological recovery, allowing for future 5-FU therapy at lower doses.

Area of Science:

  • Neuro-oncology
  • Clinical Pharmacy
  • Chemotherapy Adverse Events

Background:

  • 5-fluorouracil (5-FU) is a widely used chemotherapeutic agent.
  • Neurological complications from 5-FU are uncommon but can be severe.
  • Continuous infusion 5-FU regimens are associated with specific toxicity profiles.

Observation:

  • A rare case of acute encephalopathy was observed in a patient receiving continuous 5-FU infusion.
  • The patient presented with neurological symptoms attributed to 5-FU toxicity.
  • The exact cause of this 5-FU-induced encephalopathy remains unclear.

Findings:

  • The observed encephalopathy associated with 5-FU demonstrated reversibility.
  • Neurological recovery was expedited by the administration of steroids and thiamine.

Related Experiment Videos

  • The event did not necessarily contraindicate future treatment with 5-FU.

    • Implications:

    • This case highlights the importance of recognizing rare neurological side effects of 5-FU.
    • Prompt recognition and intervention with steroids and thiamine can improve patient outcomes.
    • Careful dose reduction may allow for continued 5-FU therapy in patients who experience this adverse event.